News
News
For more information about the history of the company and our technology, click here.
May 29, 2020
– Data reinforce potential of FCR001 to induce long-lasting immune tolerance to donated organ – BOSTON, Mass., May 29, 2020... READ MORE
December 6, 2019
BOSTON, Mass., and LOUISVILLE, Ky., Dec. 6, 2019 – Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell... READ MORE
November 7, 2019
BOSTON, Mass., and LOUISVILLE, Ky., Nov. 7, 2019 – Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell... READ MORE
October 23, 2019
Pivotal trial to evaluate the safety and efficacy of novel, investigational cell therapy intended to durably free living donor kidney... READ MORE
September 26, 2019
BOSTON, Mass., and LOUISVILLE, Ky., Sept. 26, 2019 – Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell... READ MORE
September 18, 2019
BOSTON, Mass., and LOUISVILLE, Ky., September 18, 2019 – Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell... READ MORE
June 2, 2019
BOSTON, Mass., and LOUISVILLE, Ky., June 2, 2019 – Talaris Therapeutics, Inc., a privately held biotechnology company developing transformative cell... READ MORE
April 18, 2019
Financing will support Phase 3 trial of FCR001 for living donor kidney transplant patients and additional Phase 2 studies in... READ MORE
April 18, 2019
FCR001 established durable immune tolerance in 70% of patients Results support initiation of Phase 3 registration study later this year... READ MORE